Previous 10 | Next 10 |
Resmetirom new drug application (NDA) filing on track for Q2 2023 Resmetirom has received Breakthrough Therapy designation from FDA Multiple resmetirom abstracts accepted for presentation at EASL, including primary results and additional data from the Phase 3 MAESTRO-NASH trial ...
2023-05-07 10:05:43 ET Summary AKRO will produce phase 2b SYMMETRY data in 4Q, but phase 3 will be a few years away. I believe Madrigal's success and the far off phase 3 may dampen exuberance around SYMMETRY. However, SYMMETRY will prove its cirrhosis activity, so there may we...
2023-04-26 11:30:00 ET With a wave of patent expirations set to sting some of the biggest drugmakers, pharma companies have been steadily turning to mergers and acquisitions to fill key holes in their pipelines and product portfolios. This year, for example, Pfizer paid a whopping $43 b...
2023-04-25 13:50:22 ET Summary Obeticholic acid (OCA) has shown potential for treating NASH with fibrosis, demonstrating improvements in liver histology, inflammation, and steatosis. Safety concerns, including liver injury and worsening cardiometabolic risk factors, raise doubts a...
2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...
2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...
2023-04-20 14:06:25 ET Shares of clinical-stage biotech Madrigal Pharmaceuticals (NASDAQ: MDGL) rose by a noteworthy 20% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence . The biotech's stock took flight ...
2023-04-18 19:18:43 ET The latest barrage of earnings reports failed to move the overall stock market, as the major U.S. equity averages finished the session nearly unchanged. The S&P 500 edged up less than 0.1%. Despite the general malaise, travel stocks managed to push higher. Thi...
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 10.76% on the day to $284.15. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the...
2023-04-18 08:31:08 ET The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to Madrigal Pharmaceuticals' ( NASDAQ: MDGL ) resmetirom to treat patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. The company also said ...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...